Vanguard Group Inc. Sells 281,273 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Vanguard Group Inc. trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,432,247 shares of the biopharmaceutical company’s stock after selling 281,273 shares during the period. Vanguard Group Inc. owned 0.07% of Catalyst Pharmaceuticals worth $196,809,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of CPRX. Rothschild Investment LLC grew its holdings in Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,520 shares during the period. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals during the third quarter valued at $39,000. Quarry LP bought a new position in Catalyst Pharmaceuticals during the third quarter valued at $40,000. Financial Life Planners bought a new position in Catalyst Pharmaceuticals during the third quarter valued at $42,000. Finally, First Horizon Corp bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $52,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals News Summary

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $31.15 on Friday. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $32.56. The business has a fifty day moving average price of $25.31 and a 200-day moving average price of $23.93. The firm has a market capitalization of $3.81 billion, a P/E ratio of 18.43, a PEG ratio of 1.01 and a beta of 0.72.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a report on Thursday. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $31.50 in a report on Friday. Three research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $32.17.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).